Tampa, Fla. (October 26, 2005) - Nanobac Life Sciences, Inc. (OTCBB: NNBP) (“Nanobac” or “the Company”) announced today the introduction of two new versions of its NANOCAPTURE™ and NANO-SERO™ ELISA test kits for the detection of Calcifying Nano-Particles (CNPs), also known as nanobacteria, in serum or plasma. The new kits offer improved sensitivity, lower background and improved stability over the previous versions. Nanobac has added new standards to improve precision at the low end and freeze dried the critical components for improved stability.
“Our demand for CNP diagnostic products is increasing as CNP’s or nanobacteria are implicated in more and more chronic diseases,” stated Grant Carlson, Nanobac’s President and Chief Operating Officer. “Nanobac has worked hard to develop robust, sensitive and reproducible ELISA test kits for the CNP/nanobacteria research community. These kits are CE marked and ready for immediate shipment throughout the European Union. In the United States the kits will be sold For Research Use Only (RUO).”
The NANOCAPTURE ELISA is a two-site immunoenzymatic assay for the quantitative measurement of CNP/nanobacterial antigen in serum or plasma. The NANO-SERO ELISA is also a two site immunoenzymatic assay for the quantitative measurement of anti-CNP antibodies in serum or plasma. Nanobac will feature the NANOCAPTURE and NANO-SERO ELISA test kits at the world’s #1 medical trade show, MEDICA, in Dusseldorf, Germany, November 16-19, 2005. Last year the show attracted 136,000 visitors from around the world. Nanobac intends to meet with potential customers and establish its global network of in vitro diagnostic distributors.
Nanobac Life Sciences, Inc. is a broad-based life science company that discovers, develops, manufactures, and markets a range of products and services to improve people’s health through the detection and treatment of Calcifying Nano-Particles, otherwise known as “nanobacteria”. The Company’s pioneering research is establishing the pathogenic role of nanobacteria in soft tissue calcification, particularly in coronary artery heart disease, prostatitis and vascular disease.
Nanobac manufactures and markets In Vitro Diagnostic (IVD) kits and reagents for the detection of Calcifying Nano-Particles. IVD products include the NANOCAPTURE™ and NANO-SERO™ ELISA assays and the Nano-Vision™ line of antibodies and reagents. Nanobac’s BioAnalytical Services works with biopharmaceutical partners to develop and apply methods for avoiding, detecting, and inactivating or eliminating CNPs from raw materials. Nanobac’s Drug Discovery and Development efforts are focused on developing new and existing compounds that effectively inhibit, destroy or neutralize CNPs. The Company also markets Dietary Supplements through its subsidiary, Nanobac Sciences, LLC.
Nanobac Life Sciences, Inc. is headquartered in Tampa, Florida. For more information, please visit our website at: http://www.nanobac.com.
Investors are cautioned that certain statements contained in this document as well as some statements in periodic press releases and some oral statements of Nanobac Life Sciences, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Life Sciences, Inc. actions, which may be provided by management, are also forwardlooking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Life Sciences, Inc. has no specific intention to update these statements.